Anika Therapeutics Inc. (ANIK)
ANIK trades on Nasdaq in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/0001171843-26-001275-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ANIK on Nasdaq |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000898437 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $112.8M |
| Net income | -$10.9M |
| Operating income | -$11.1M |
| Net margin | -9.6% |
| Operating margin | -9.8% |
| Revenue growth | -5.9% |
| Cash | $57.5M |
| Total assets | $190.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-06 |
| Cash and burn | $45.0M cash; operating cash flow $1.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 13,395,313 (2026-10-30); 14,421,219 a year earlier; 14,640,886 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $264K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $30.6M | -$311K | $8.4M | $45.0M | No debt tags | $123.4M | 10-Q 2026-11-06 |
| Q2 2026 2026-06-30 | $32.6M | $3.3M | -$684K | $38.4M | No debt tags | $120.7M | 10-Q 2026-07-29 |
| Q1 2026 2026-03-31 | $29.6M | -$5.1M | -$4.8M | $41.0M | No debt tags | $116.3M | 10-Q 2026-04-30 |
| Q4 2025 2025-12-31 | $30.6M | $292K | $4.6M | $57.5M | No debt tags | $112.8M | 10-K 2026-03-03 |
| Q3 2025 2025-09-30 | $27.8M | -$2.3M | $6.9M | $58.0M | No debt tags | $112.8M | 10-Q 2026-11-06 |
| Q2 2025 2025-06-30 | $28.2M | -$4.0M | -$189K | $53.2M | No debt tags | $114.5M | 10-Q 2026-07-29 |
| Q1 2025 2025-03-31 | $26.2M | -$4.9M | -$130K | $53.4M | No debt tags | $117.1M | 10-Q 2026-04-30 |
| Q4 2024 2024-12-31 | $30.6M | -$21.9M | $1.6M | $55.6M | No debt tags | $119.9M | 10-K 2026-03-03 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest annual report FORM 10-K | 10-K | 2026-03-03 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-06 |
| Latest current report FORM 8-K | 8-K | 2026-11-06 |
| Latest proxy | DEFA14A | 2026-06-08 |
Source: SEC EDGAR submissions feed, 1,006 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -7.9% |
| 1 month | -34.7% |
| 3 months | -36.7% |
| Year to date | +39.4% |
| 1 year | +32.7% |
| From 52-week high | -39.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| KRMD | KORU Medical Systems Inc. Common Stock (DE) | $3.69 | -0.27% | $160.1M |
| KTWO | K2 Capital Acquisition Corporation Class A Ordinary Share | $10.13 | +0.05% | $203.0M |
| UTMD | Utah Medical Products Inc. | $72.36 | +0.54% | $206.2M |
| PDEX | Pro-Dex Inc. | $64.48 | -1.80% | $206.3M |
| PYPD | PolyPid Ltd. | $6.15 | -1.76% | $124.9M |
| LUNG | Pulmonx Corporation | $2.80 | -2.10% | $121.9M |
| STIM | Neuronetics Inc. | $1.25 | -10.07% | $120.6M |
| OSUR | OraSure Technologies Inc. | $3.60 | -0.55% | $248.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier